The prediction of tumor response to chemotherapy can be achieved by elucidating the efficiency of drug delivery to the targeted tumor cells, and the effectiveness of the delivered drug to be activated and act on tumor cells. A non-invasive means that can answer these questions is essential for designing efficient and personalized therapy, and is especially crucial to improve the efficacy of treating pancreatic ductal adenocarcinoma (PDAC), one of the most lethal human malignancies. In the present study, we propose to develop a highly translatable MRI technology to answer the two questions mentioned above in the gemcitabine treatment of PADC, and hence to predict tumor responses. In particular, Our approach is based on a so-called Chemical Exchange Saturation Transfer (CEST) MRI contrast mechanism, by which drugs are imaged directly by their inherently carried exchangeable protons (OH, NH or NH2), at a detectability comparable to that for Gd-based agents. Formulated on the basis of our preliminary results, we hypothesize that agents that contain cytosine and cytidine, for instance gemcitabine, can be detected using CEST MRI, namely cytCEST. We anticipate our approach can be used to predict tumor response to the gemcitabine treatment by assessing the accumulation, biodistribution and retention of the drug in the tumor, without the need for imaging tags or additional agents. To achieve our goal, we will first optimize and validate the cytCEST MRI detection of tumor uptake and biodistribution of gemcitabine. Then we will develop cytCEST MRI as an effective means to detect the activity of deoxycytidine kinase (dCK), one of the most important drug-resistance-related enzymes. Finally the potential of cytCEST MRI to predict the response of pancreatic tumors to therapy will be examined on the treatment in KPC genetically engineered mouse models using three different gemcitabine-based treatments. Successful completion of this project will result in an imaging tool for the prediction of tumor response to gemcitabine using the drug or its analog deoxycytidine directly as the imaging agent, namely label-free because no chemical-modification is needed. It is expected that such a label-free approach can be rapidly translated to the clinic, allowing clinicians to stratify patients prior to (or immediately after) the administration of gemcitabine or other cytosine- or cytidine-based chemotherapeutic drugs and to choose the personalized treatment plan for each group of patients.

Public Health Relevance

The project is relevant to public health because it is expected to result in a highly translatable medical imaging technology for non-invasively and early predicting the response of tumors, for instance pancreatic ductal adenocarcinoma (PDAC), to a gemcitabine-based chemotherapy. This proposed technology directly detect gemcitabine or its analog deoxycytidine using a technique called chemical exchange saturation transfer (CEST), without the need for extra chemical-, paramagnetic-, or radioactive- imaging labeling. It is expected that the proposed label-free approach, once established, can be rapidly translated to the clinic, allowing clinicians to stratify patients prior to (or immediately after) the administration of gemcitabine or other cytidine-based chemotherapeutic drug and to choose an appropriate treatment plan in the manner of personalized medicine.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Biomedical Imaging Technology Study Section (BMIT)
Program Officer
Zhang, Huiming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Hugo W. Moser Research Institute Kennedy Krieger
United States
Zip Code
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Liu, Jing; Bai, Renyuan; Li, Yuguo et al. (2018) MRI detection of bacterial brain abscesses and monitoring of antibiotic treatment using bacCEST. Magn Reson Med 80:662-671
Zhang, Jia; Li, Yuguo; Slania, Stephanie et al. (2018) Phenols as Diamagnetic T2 -Exchange Magnetic Resonance Imaging Contrast Agents. Chemistry 24:1259-1263
Ryoo, David; Xu, Xiang; Li, Yuguo et al. (2017) Detection and Quantification of Hydrogen Peroxide in Aqueous Solutions Using Chemical Exchange Saturation Transfer. Anal Chem 89:7758-7764
Liu, Guanshu; Ray Banerjee, Sangeeta; Yang, Xing et al. (2017) A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen. Nat Biomed Eng 1:977-982
Lock, Lye Lin; Li, Yuguo; Mao, Xinpei et al. (2017) One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging Agents. ACS Nano 11:797-805